163266-02-2

Basic information

• Product Name: 4,4,4-trifluoro-1-(2-methylphenyl)butane-1,3-dione
• Synonyms: 4,4,4-trifluoro-1-(2-methylphenyl)butane-1,3-dione;4,4,4-TRIFLUORO-1-(2-METHYLPHENYL)-1,3-BUTANEDIONE;4,4,4-Trifluoro-1-(o-tolyl)butane-1,3-dione;Celecoxib Impurity 5;Moxifloxacin impurity 13
• CAS NO: 163266-02-2
• Molecular Formula: C₁₁H₉F₃O₂
• Molecular Weight: 230.184
• Mol File: 163266-02-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 264.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.252±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 5.77±0.23(Predicted)
• CAS DataBase Reference: 4,4,4-trifluoro-1-(2-methylphenyl)butane-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4,4-trifluoro-1-(2-methylphenyl)butane-1,3-dione(163266-02-2)
• EPA Substance Registry System: 4,4,4-trifluoro-1-(2-methylphenyl)butane-1,3-dione(163266-02-2)

Safety Data

• Hazardous Substances Data: 163266-02-2(Hazardous Substances Data)

Usage

Uses

4,4,4-Trifluoro-1-(2-methylphenyl)-1,3-butanedione is a useful synthetic intermediate in the synthesis of 4-Desmethyl-2-methyl Celecoxib (D291815); an analog of Celecoxib (C251000) which is a cyclooxygenase 2 inhibitor.

Upstream product

• 577-16-2 2-Methylacetophenone 
• 407-38-5 2,2,2-trifluoroethyl trifluoroacetate 
• 383-63-1 ethyl trifluoroacetate, 

Downstream Products

• 41441-74-1 o-methyl-α-diazoacetophenone 

Relevant articles and documents

An SAR study of hydroxy-trifluoromethylpyrazolines as inhibitors of Orai1-mediated store operated Ca2+ entry in MDA-MB-231 breast cancer cells using a convenient Fluorescence Imaging Plate Reader assay

The proteins Orai1 and STIM1 control store-operated Ca2+ entry (SOCE) into cells. SOCE is important for migration, invasion and metastasis of MDA-MB-231 human triple negative breast cancer (TNBC) cells and has been proposed as a target for cancer drug discovery. Two hit compounds from a medium throughput screen, displayed encouraging inhibition of SOCE in MDA-MB-231 cells, as measured by a Fluorescence Imaging Plate Reader (FLIPR) Ca2+ assay. Following NMR spectroscopic analysis of these hits and reassignment of their structures as 5-hydroxy-5-trifluoromethylpyrazolines, a series of analogues was prepared via thermal condensation reactions between substituted acylhydrazones and trifluoromethyl 1,3-dicarbonyl arenes. Structure-activity relationship (SAR) studies showed that small lipophilic substituents at the 2- and 3-positions of the RHS and 2-, 3- and 4-postions of the LHS terminal benzene rings improved activity, resulting in a novel class of potent and selective inhibitors of SOCE.

Synthesis of 4-[5-(2-methylphenyl)-3-(trifluoromethyl)-1-hydro-pyrazol-1-yl] benzenesulfonamide

The invention discloses a synthesis method of 4-[5-(2-methylphenyl)-3-(trifluoromethyl)-1-hydro-pyrazol-1-yl] benzenesulfonamide. The synthesis method comprises the following steps: with methyl acetophenone as a starting raw material, under a strong alkal

Keto-enol and enol-enol tautomerism in trifluoromethyl-β-diketones

The keto-enol (K?E) and enol-enol (E?E) equilibria of a variety of trifluoromethyl-β-diketones were investigated using 1H, 13C, 19F NMR spectroscopy, infrared spectroscopy and ultraviolet-visible spectrophotometry in nonpolar solvents. In general, NMR, IR and UV spectral evidence indicates that trifluoromethyl-β-diketones exist as mixtures of two chelated cis-enol forms in nonpolar media. Infrared spectroscopy and ultraviolet spectrophotometry show the E?E equilibrium lies in the direction of the enol form which maximizes conjugation in most cases. Exceptions are noted and discussed.